Honokiol Inhibits the Inflammatory Response and Lipid Metabolism Disorder by Inhibiting p38α in Alcoholic Liver Disease

Abstract

Alcoholic liver disease is one of the leading causes of liver-related morbidity and mortality worldwide, but effective treatments are still lacking. Honokiol, a lignin-type natural compound isolated from the leaves and bark of Magnolia plants, has been widely studied for its beneficial effects on several chronic diseases. Accumulating studies have revealed that honokiol displays a potential therapeutic effect on alcoholic liver disease. In this study, the protective activity of honokiol on alcoholic liver disease was confirmed due to its significant inhibitory activity on the expression levels of inflammatory cytokines (such as tumor necrosis factor-alpha, interleukin-6, and interleukin-1β) in EtOH-fed mice and in EtOH-induced AML-12 cells. Meanwhile, the expression of the lipid metabolic parameter sterol regulatory element-binding protein-1c was also reduced. However, peroxisome proliferator-activated receptor α was increased in animal and cell experiments, which indicates that the activity of honokiol was related to its regulated activity on lipid metabolism. The result showed that honokiol significantly inhibited the expression level of p38α in vivo and in vitro. Blocking p38α inhibited the expression levels of tumor necrosis factor-alpha, interleukin-6, interleukin-1β, and sterol regulatory element-binding protein-1c but promoted the expression level of peroxisome proliferator-activated receptor α compared with the honokiol-treated group. Moreover, the forced expression level of p38α further produced the opposite effect on inflammatory cytokines and lipid metabolism indicators. Furthermore, p38α has been related to the activation of the nuclear factor kappa B signaling pathway. In our study, honokiol significantly inhibited the activation of the nuclear factor kappa B signaling pathway mediated by p38α. In conclusion, the results suggest that honokiol might be an effective regulator of p38α by downregulating the nuclear factor kappa B signaling pathway, thereby reducing the inflammatory response and lipid metabolism disorder in alcoholic liver disease.

Key words

honokiol - alcoholic liver disease - p38α - inflammation - lipid metabolism - NF-κB - Magnolia officinalis - Magnoliaceae

Publication History

Received: 04 March 2022

Accepted after revision: 17 June 2022

Accepted Manuscript online:
17 June 2022

Article published online:
23 January 2023

• References

• 1 Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol 2015; 62: S38-S46
• 2 Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223-2233
• 3 Xu MJ, Zhou Z, Parker R, Gao B. Targeting inflammation for the treatment of alcoholic liver disease. Pharmacol Ther 2017; 180: 77-89
• 4 Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res 2020; 61: 470-479
• 5 Hu S, Li SW, Yan Q, Hu XP, Li LY, Zhou H, Pan LX, Li J, Shen CP, Xu T. Natural products, extracts and formulations comprehensive therapy for the improvement of motor function in alcoholic liver disease. Pharmacol Res 2019; 150: 104501
• 6 Yin HQ, Kim YC, Chung YS, Kim YC, Shin YK, Lee BH. Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes. Toxicol Appl Pharmacol 2009; 236: 124-130
• 7 Liu SY, Tsai IT, Hsu YC. Alcohol-related liver disease: basic mechanisms and clinical perspectives. Int J Mol Sci 2021; 22: 5170
• 8 Hu S, Liu YM, Chen-Chen, Li LY, Zhang BY, Yang JF, Li HD, Meng XM, Jun-Li. Xu T, Zhou H. MicroRNA-708 prevents ethanol-induced hepatic lipid accumulation and inflammatory reaction via direct targeting ZEB1. Life Sci 2020; 258: 118147
• 9 Li LY, Yang CC, Li SW, Liu YM, Li HD, Hu S, Zhou H, Wang JL, Shen H, Meng XM, Li J, Xu T. TMEM88 modulates the secretion of inflammatory factors by regulating YAP signaling pathway in alcoholic liver disease. Inflamm Res 2020; 69: 789-800
• 10 Zhu Q, Huang C, Meng X, Li J. CYP1A2 contributes to alcohol-induced abnormal lipid metabolism through the PTEN/AKT/SREBP-1c pathway. Biochem Biophys Res Commun 2019; 513: 509-514
• 11 Meng FG, Zhang XN, Liu SX, Wang YR, Zeng T. Roles of peroxisome proliferator-activated receptor alpha in the pathogenesis of ethanol-induced liver disease. Chem Biol Interact 2020; 327: 109176
• 12 Yeh WJ, Tsai CC, Ko J, Yang HY. Hylocereus polyrhizus peel extract retards alcoholic liver disease progression by modulating oxidative stress and inflammatory responses in C57BL/6 mice. Nutrients 2020; 12: 3884
• 13 Nowak AJ, Relja B. The impact of acute or chronic alcohol intake on the NF-κB signaling pathway in alcohol-related liver disease. Int J Mol Sci 2020; 21: 9407
• 14 Ali EMH, Abdel-Maksoud MS, Hassan RM, Mersal KI, Ammar UM, Se-In C, He-Soo H, Kim HK, Lee A, Lee KT, Oh CH. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38alpha/MAPK14 inhibitor. Bioorg Med Chem 2021; 31: 115969
• 15 Madkour MM, Anbar HS, El-Gamal MI. Current status and future prospects of p38alpha/MAPK14 kinase and its inhibitors. Eur J Med Chem 2021; 213: 113216
• 16 Canovas B, Nebreda AR. Diversity and versatility of p38 kinase signalling in health and disease. Nat Rev Mol Cell Biol 2021; 22: 346-366
• 17 Fortier M, Cadoux M, Boussetta N, Pham S, Donne R, Couty JP, Desdouets C, Celton-Morizur S. Hepatospecific ablation of p38alpha MAPK governs liver regeneration through modulation of inflammatory response to CCl4-induced acute injury. Sci Rep 2019; 9: 14614
• 18 Darlyuk-Saadon I, Bai C, Heng CKM, Gilad N, Yu WP, Lim PY, Cazenave-Gassiot A, Zhang Y, Wong WSF, Engelberg D. Active p38alpha causes macrovesicular fatty liver in mice. Proc Natl Acad Sci U S A 2021; 118: e2018069118
• 19 Chen C, Zhang QW, Ye Y, Lin LG. Honokiol: A naturally occurring lignan with pleiotropic bioactivities. Chin J Nat Med 2021; 19: 481-490
• 20 Elfeky MG, Mantawy EM, Gad AM, Fawzy HM, El-Demerdash E. Mechanistic aspects of antifibrotic effects of honokiol in Con A-induced liver fibrosis in rats: Emphasis on TGF-beta/SMAD/MAPK signaling pathways. Life Sci 2020; 240: 117096
• 21 Yu FL, Wu JW, Zhu H. Honokiol alleviates acetaminophen-induced hepatotoxicity via decreasing generation of acetaminophen-protein adducts in liver. Life Sci 2019; 230: 97-103
• 22 Zhong X, Liu H. Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor gamma. J Gastroenterol Hepatol 2018; 33: 524-532
• 23 Tang P, Sun Q, Yang H, Tang B, Pu H, Li H. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer. Int J Pharm 2018; 545: 74-83
• 24 Petagine L, Zariwala MG, Patel VB. Alcoholic liver disease: Current insights into cellular mechanisms. World J Biol Chem 2021; 12: 87-103
• 25 Lee JS, OʼConnell EM, Pacher P, Lohoff FW. PCSK9 and the Gut-Liver-Brain Axis: A Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder. J Clin Med 2021; 10: 1758
• 26 Wang H, Zhang Y, Bai R, Wang M, Du S. Baicalin attenuates alcoholic liver injury through modulation of hepatic oxidative stress, inflammation and sonic hedgehog pathway in rats. Cell Physiol Biochem 2016; 39: 1129-1140
• 27 Tang R, Yang Q, Lin S, Feng Y, Yang J, Lv Q, Wu G, Hu J. Preventive or Curative Administration of Taurine Regulates Lipid Metabolism in the Liver of Rats with Alcoholic Liver Disease. Adv Exp Med Biol 2019; 1155: 119-131
• 28 Yang HX, Shang Y, Jin Q, Wu YL, Liu J, Qiao CY, Zhan ZY, Ye H, Nan JX, Lian LH. Gentiopicroside ameliorates the progression from hepatic steatosis to fibrosis induced by chronic alcohol intake. Biomol Ther (Seoul) 2020; 28: 320-327
• 29 Igea A, Nebreda AR. The stress kinase p38α as a target for cancer therapy. Cancer Res 2015; 75: 3997-4002
• 30 Hui L, Bakiri L, Stepniak E, Wagner EF. p38alpha: A suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007; 6: 2429-2433
• 31 Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 2002; 3: 69-75
• 32 Papachristou DJ, Papadakou E, Basdra EK, Baltopoulos P, Panagiotopoulos E, Papavassiliou AG. Involvement of the p38 MAPK-NF-kappaB signal transduction pathway and COX-2 in the pathobiology of meniscus degeneration in humans. Mol Med 2008; 14: 160-166
• 33 Wu HM, Ni XX, Xu QY, Wang Q, Li XY, Hua J. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-kappaB signaling pathway. J Gastroenterol Hepatol 2020; 35: 1998-2008
• 34 Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 2005; 30: 43-52
• 35 Yang SR, Hsu WH, Wu CY, Shang HS, Liu FC, Chen A, Hua KF, Ka SM. Accelerated, severe lupus nephritis benefits from treatment with honokiol by immunoregulation and differentially regulating NF-κB/NLRP3 inflammasome and sirtuin 1/autophagy axis. FASEB J 2020; 34: 13284-13299
• 36 Wen J, Wang X, Pei H, Xie C, Qiu N, Li S, Wang W, Cheng X, Chen L. Anti-psoriatic effects of Honokiol through the inhibition of NF-kappaB and VEGFR-2 in animal model of K14-VEGF transgenic mouse. J Pharmacol Sci 2015; 128: 116-124
• 37 Zhang P, Liu X, Zhu Y, Chen S, Zhou D, Wang Y. Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-kappaB activation and cytokine production of glial cells. Neurosci Lett 2013; 534: 123-127
• 38 Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2013; 8: 627-637